1 SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate SAPA-GP Webinar Program A Professional Training.

Slides:



Advertisements
Similar presentations
Ferring Controlled Therapeutics
Advertisements

Dr. M. Iwasaki 1 Asian Multinational Clinical Trials - Current Status & Future Direction - Dr.Masaru IWASAKI PR Japan Operations Center Aventis Pharma,
Alternative Careers in Pharma and Biotechnology Douglas Buckley Ph.D. May 13, 2011 Alternative Career Symposium Baylor College of Medicine.
Introduction to Pharmacy Course Teacher: Asim Kumar Bepari.
Asia Consortium Regional chapter in Asia ISPOR-INDIA Chapter Jawahar Bapna PhD, MD, MBBS Adjunct Professor, Pharmaceutical Management Institute of Health.
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
Consulting for Life Sciences 1 Confidential October 14, 2014 Strategic Science and Technology Capabilities Discussion
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
Pharmacy at Manchester Pharmacy at Manchester Dr Antony D’Emanuele, Senior Lecturer Dr Rachel Elliott, Clinical Lecturer School of Pharmacy and Pharmaceutical.
Clinical Research Training
INTRODUCTION TO RA.
ACCREDITED CONSULTANTS PVT LTD. (ACPL) WELCOMES YOU.
IBCT was founded in Dedicated Members of Staff including 30 Senior Consultant Specialists IBCT Consultants are the largest team in the industry.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
IB Business & Management Business Functions and Organisation.
MEDICAL experts INDUSTRY Some of our clients. Pharmaceutical companies, manufacturers of medical and surgical devices, clinical research organizations,
Discovery Phase An Introduction to the Class of 2012 Discovery Phase Co-Directors Maureen Powers, Ph.D. Henry M. Blumberg, M.D.
China Healthcare Consulting Inc. Creating Value for Our Clients Boston Healthcare Associates, Inc. 75 Federal Street, 9 th Floor.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
Discovery Phase An Introduction for the Class of 2015 Discovery Phase Co-Directors Maureen Powers, Ph.D. Henry M. Blumberg, M.D.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Industry-Friendly Resumés Tips and Pitfalls Pejman Azarmina, MD MSc Sr. Director & Team Leader Pfizer Inc.
11/15/20151 Who We Are: Arunava (Ron) Sanyal, M.Pharm,CQE, RAC CEO/President
HUG Regulatory/Government Affairs Team Jackie Elkin, Medtronic June 20, 2005.
Strategic Drug Repositioning Exploit Opportunities and Accelerate R&D by Re-profiling Your Drugs ____________________________ +1.
Molecule-to-Market-Place Quality
Use of Imaging Biomarkers for Regulatory Studies by Peter Steiger J Bone Joint Surg Am Volume 91(Supplement 1): February 1, 2009 ©2009 by The Journal.
 Human Resources  Sales and Marketing  Research and Development  Production/Operations  Customer Service  Finance and Accounts  Administration.
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
MEDICAL STUDENT TRANSITION COURSE Professionalism in the Clinical Environment ANTHONY A. MEYER, MD, PHD CHAIRMAN, DEPARTMENT OF SURGERY UNIVERSITY OF NORTH.
FDA Regulatory and Compliance Symposium
 What makes a good presentation?  What do you need to do?  Who does what?
Dr. Samuel Dyer - Chairman of the Board - Medical Science Liaison Society MSL What is a Medical Science Liaison? (What Do.
Progression of New Drug: From Idea to Public Consumption Chris DeFarlo Writing in the HLTH Professions Unit 2 Prof. Edwards.
Cognitive Impairment Associated With Schizophrenia (CIAS)Pipeline Review, H Published on : October No. Pages : 110.
Medical Writing Special Interest Area Community (SIAC) Medical Communications March Workshop 2012 David Clemow SIAC Chair Melissa Ossanna Communications.
Aarkstore - Metastatic Ovarian Cancer- Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Category : Pharmaceuticals and Healthcare.
Today’s programme 10:00 – 10:15Welcome speeches and introductions 10:15 – 10:45Boosting the employability of your graduates 10:45 – 11:15Development of.
Regulatory Submissions to Asian Countries DIA MW All-SIAC Telecon Thursday 06 May :00 AM (PDT)
© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.
Evercare Quality Improvement Awards James Collins, M.D. Julie Hayes, R.N. Randy Muenzner.
David J. Hauss, PhD, RPh Regeneron Pharmaceuticals, Inc. Tarrytown, NY.
Setting the Stage: Ten of the Toughest Compliance Questions in Medical and Clinical Affairs International Pharmaceutical Compliance Summit March 30, 2005.
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
Rigid Endoscopes : Medical Device Industry Research And Analysis
Endoscopy Visualization Systems - Medical Devices Pipeline Assessment
Positron Emission Tomography (PET) Systems - Medical Devices Pipeline Assessment, 2016
Nucleus Replacement Medical Devices Market Size, Share & Forecast
Global Norepinephrine Reuptake Inhibitor Market Outlook, Demand Supply and 2021 Forecast Published: Nov 2016 Single User License: US$ 2900 Corporate User.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
Developing and Broadening Specialists in Research & Development
Careers in Pharmaceutical Regulatory Affairs
The IFPMA Code and how to set up a national self-regulation system Presentation to China/EU Pharmaceutical Industry Forum 17 May 2017, Shanghai, China.
DIA Clinical Safety and Pharmacovigilance Community
NIHR Invention for Innovation (i4i)
June 2016 Employer brand.
Dr. Siegfried Bialojan Background Skills Professional experience
CTD Content Management
Inspection Preparation 9th January 2017
DIA Clinical Safety and Pharmacovigilance Community
Novartis Pediatric Drug Development Faculty Program
Business Functions and Organisation
INTERNATIONAL CONFERENCE ON PHARMACEUTICAL RESEARCH AND DEVELOPMENT
Welcome to US Physiatry
Measuring R&D Impact: Dilemma between reality and expectations
Intl Director of Campaigns Director of Policy & External Affairs
Data & Learning Team February 1, 2018.
Welcome! We will begin shortly.
Medical Affairs The Challenge, Our Resources, The Future
Global Immunosuppressive Drug Market Research an Forecast
Presentation transcript:

1 SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate SAPA-GP Webinar Program A Professional Training Tool for SAPA Members Non-members are Welcome to Participate January, 2013 Introduction of Early Drug Development Dr. Sean Zhang, MD, FCP Medical Director, Bristol-Myers Squibb (BMS) February, 2013 Late Stage of Clinical Drug Development, e.g., Ph 2b/3 Studies/Strategies Dr. Joan Shen, MD. PhD. Senior Medical Director, China Clinical Lead, PCBU Pfizer Inc. April, 2013 Regulatory Requirements for the CTA of Multinational Clinical Trials in China Dr. Cathleen CHAN/ 陈明 Regulatory Director, Sanofi R&D China

2 Regulatory Requirements for the CTA of Multinational Clinical Trials in China April. 16 th, 2013 SAPA-GP Webinar Program Cathleen CHAN, MD. Regulatory Director, Regulatory R&D China, GRA Sanofi R&D

3 Background Dr. Chan is a physician. She starts her career in the sales and marketing in the pharmaceutical and medical device industry in China Dr. Chan has worked as the regional head in the sales and marketing for the North of China, director in regulatory and government affairs for China and Asia Dr. Chan gained her broad regulatory experience in Servier and Sanofi, where she is the head in regulatory, responsible for IND, NDA and LCM for Asia and China Dr. Chan has been very devoted to Multinational Clinical Trial Applications for global and regional clinical trials with the CFDA in the last 10 years Dr. Chan leads Asian regional and China R&D regulatory team in regulatory strategy and operation for Sanofi, success in shorting the CTA review timeline by improving internal practice and collaborating with academy, associations in China

4 Presentation Outlines: General Regulatory Requirements for the Multinational Clinical Trials Hurdles of CTA for the Multinational Clinical Trials for IND in China Description of China CTA Package contents – CFDA requirement How to Prepare an China CTA Package Based on EU/IMPD (Investigational Medical Product Document) or US/IND package